JPH02212429A - Hemoferrum-containing composition - Google Patents
Hemoferrum-containing compositionInfo
- Publication number
- JPH02212429A JPH02212429A JP1032635A JP3263589A JPH02212429A JP H02212429 A JPH02212429 A JP H02212429A JP 1032635 A JP1032635 A JP 1032635A JP 3263589 A JP3263589 A JP 3263589A JP H02212429 A JPH02212429 A JP H02212429A
- Authority
- JP
- Japan
- Prior art keywords
- hemoferrum
- iron
- heme iron
- cyclodextrin
- cyclodextrins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 145
- 229910052742 iron Inorganic materials 0.000 claims abstract description 73
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 39
- 229940097362 cyclodextrins Drugs 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000003278 haem Chemical class 0.000 claims description 56
- 239000000463 material Substances 0.000 claims description 24
- 239000000126 substance Substances 0.000 abstract description 22
- 239000000843 powder Substances 0.000 abstract description 20
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 11
- 238000003756 stirring Methods 0.000 abstract description 11
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 9
- 239000001116 FEMA 4028 Substances 0.000 abstract description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract description 7
- 229960004853 betadex Drugs 0.000 abstract description 7
- 230000000873 masking effect Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 235000019640 taste Nutrition 0.000 abstract description 6
- 238000004898 kneading Methods 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 239000007787 solid Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000011369 resultant mixture Substances 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 description 12
- 108010054147 Hemoglobins Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000004570 mortar (masonry) Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- -1 iron complex salt Chemical class 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZCFFYALKHPIRKJ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical group N1C(C=C2C(=C(C)C(=CC=3C(C)=C(CCC(O)=O)C(N=3)=C3)N2)C=C)=C(C)C(C=C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 ZCFFYALKHPIRKJ-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- 235000019697 iron containing food Nutrition 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は鉄分を摂取させるため、有機酸鉄や無機鉄より
吸収の良いヘム鉄含有物を用いて医薬品や食品、或いは
飼料、餌料を作るに際し、その特有の異味、周臭をマス
キングした服用しゃすいヘム鉄含有物を提供するもので
ある。[Detailed Description of the Invention] [Industrial Application Field] The present invention uses heme iron-containing materials, which are better absorbed than organic acid iron or inorganic iron, to make medicines, foods, feeds, and feedstuffs in order to ingest iron. The purpose of the present invention is to provide a heme iron-containing product that masks the characteristic off-taste and odor and is easy to take.
［従来の技術］
現在は飽食の時代と言われているにも拘らず、ダイエツ
トブームや食生活の変化も一因と考えられるが、女性の
約２２％は貧血で、実に全女性の約３分の１は何等かの
貧血症状を経験しているといわれている。これは鉄分摂
取不足のなめであり、保健食品として鉄含有食品の必要
性が叫ばれている。[Conventional technology] Although it is said that we are currently living in an era of satiated eating, approximately 22% of women are anemic, which is thought to be due to diet booms and changes in eating habits. It is said that 1 in 10 people experience some kind of anemia symptoms. This is a sign of insufficient iron intake, and the need for iron-containing foods as health foods has been emphasized.
ヒト赤血球のヘモグロビンは肺で酸素を受取り全身に酸
素を供給する重要な役割を担っているが、摂取する鉄分
が不足すると、体内でのヘモグロビンの合成ができなく
なり、貧血症状を示すことがある。従来種々の鉄剤が貧
血の治療用に使われていたが、無機鉄（硫酸第一鉄）、
有機酸鉄（乳酸第一鉄、グルコン酸第−鉄、フマール酸
第−鉄等）は炭酸、燐酸、蓚酸、タンニン酸、カフェイ
ン、フィチン酸、食物繊維等による吸収阻害があり、吸
収効率が食事の系にて摂取量の約５〜８％である。一方
、牛、豚等の層血ヘモグロビン由来のヘム鉄はプロトポ
ルフィリンの２価鉄錯塩（フェロプロトポルフィリン）
であり、２価の鉄イオンにイオン化してから吸収される
ことはほとんどなく、ヘムリングの形で腸管粘膜細胞に
吸収されるため、無機鉄や有機酸鉄のような吸収阻害が
みられず、摂取量の１５〜３５％が吸収される利点があ
る。また、無機鉄および有機酸鉄（以後非ヘム鉄と略す
）は腸管内でイオン化しているため、摂取量によっては
腸管粘膜の蛋白を変性し易く、悪心、胸やけ、消化器障
害、心窩部痛、吐き気、下痢、便秘等の副作用がある。Hemoglobin in human red blood cells plays an important role in receiving oxygen in the lungs and supplying oxygen throughout the body, but if there is insufficient iron intake, the body will not be able to synthesize hemoglobin, which may lead to symptoms of anemia. Conventionally, various iron preparations have been used to treat anemia, but inorganic iron (ferrous sulfate),
The absorption of organic iron acids (ferrous lactate, ferrous gluconate, ferrous fumarate, etc.) is inhibited by carbonic acid, phosphoric acid, oxalic acid, tannic acid, caffeine, phytic acid, dietary fiber, etc., and the absorption efficiency is reduced. Approximately 5 to 8% of intake comes from food. On the other hand, heme iron derived from hemoglobin in the blood of cows, pigs, etc. is a divalent iron complex salt of protoporphyrin (ferroprotoporphyrin).
It is rarely absorbed after being ionized into divalent iron ions, and is absorbed into intestinal mucosal cells in the form of hem rings, so there is no absorption inhibition like inorganic iron or organic acid iron. It has the advantage that 15-35% of the ingested amount is absorbed. In addition, inorganic iron and organic acid iron (hereinafter abbreviated as non-heme iron) are ionized in the intestinal tract, so depending on the amount ingested, they can easily denature the proteins in the intestinal mucosa, causing nausea, heartburn, digestive disorders, and epigastric iron. Side effects include pain, nausea, diarrhea, and constipation.
ヘモグロビン由来のヘム鉄にはこのような副作用がない
ばかりではなく、便通が良くなる利点がある。Heme iron derived from hemoglobin not only does not have these side effects, but also has the advantage of improving bowel movements.
以上のごとく、ヘム鉄は非ヘム鉄に比べて種々の利点が
あるために、現在貧血防止用に多量に用いられるように
なってきた。As described above, heme iron has various advantages compared to non-heme iron, and therefore, it is currently being used in large amounts for the prevention of anemia.
ところでヘム鉄含有物は牛や豚の層血を採取後、精製、
加工されるが、原料が動物の血液であることから血液由
来の異味、異臭がある。ヘム鉄含有物の異味、異臭のマ
スキングについては、ヘモグロビンの精製工程の改良（
特開昭６３〜２７６４６０号）等、ヘム鉄の純度を向上
させることが主としてなされてきた。確かに、純度の高
い製品は低純度のものと比較すると、異味、異臭の度合
いは少なくなっているが、やはりヘモグロビン蛋白質や
血液由来の異味、異臭を満足できる程度には抑えること
ができていない。したがって、ヘム鉄を比較的大量に配
合し、効果が十分期待できる量のヘム鉄を含む食品或い
は錠剤を調製すると、ヘム鉄含有物由来の異味、異臭が
問題となり、スムーズな摂取を妨げているのが現状であ
る。By the way, heme iron-containing substances are extracted from the blood of cows and pigs, purified, and
It is processed, but because the raw material is animal blood, it has a strange taste and smell derived from blood. Improvements in the hemoglobin purification process (
Efforts have been made mainly to improve the purity of heme iron, such as in JP-A-63-276460. It is true that high-purity products have less off-taste and odor than low-purity products, but the off-taste and odor derived from hemoglobin protein and blood cannot be suppressed to a satisfactory level. . Therefore, when a relatively large amount of heme iron is blended to prepare a food or tablet containing heme iron in an amount that can be expected to be effective, the problem of off-taste and odor originating from the heme iron content becomes a problem, which prevents smooth intake. is the current situation.
［本発明が解決しようとする問題点］
この異味、異臭をマスキングするために、さらに強いフ
レーバーやスパイスを一緒に配合する方法も考えられる
が、人それぞれの好みの問題もあり、万人に受は入れら
れるものができるとは限らない。そこで、ヘム鉄含有物
特有の異味、異臭を他に強い味や香りをつけることなく
、充分にマスキングする方法が強く望まれている。[Problems to be Solved by the Present Invention] In order to mask this off-taste and odor, it is possible to combine stronger flavors and spices together, but this is a matter of personal preference, so it is not possible to find a method that is acceptable to everyone. What you can put in doesn't necessarily mean what you can do. Therefore, there is a strong demand for a method that can sufficiently mask the off-taste and odor characteristic of heme iron-containing substances without imparting other strong tastes or scents.
［問題点を解決するための手段］
本発明者らは、鋭意研究の結果、ヘム鉄含有物にシクロ
デキストリン類を添加し、ヘム鉄含有物特有の異味、異
臭を効率よく包接することによりマスキングが可能であ
ることを見出だし、本発明に到達した。[Means for Solving the Problems] As a result of extensive research, the present inventors added cyclodextrins to heme iron-containing materials to effectively mask the off-taste and odor characteristic of heme iron-containing materials by including them. The inventors have discovered that this is possible, and have arrived at the present invention.
シクロデキストリン類は疎水性の空洞を分子内に有し、
種々の疎水性物質をその空洞内に包接することにより、
その物質の性質を変えることはよく知られている。本発
明はヘム鉄含有物にシクロデキストリン類を添加し、水
の存在下、攪拌、混練することにより、ヘム鉄含有物と
シクロデキストリン類を含有してなる組成物に関する。Cyclodextrins have a hydrophobic cavity in their molecules,
By including various hydrophobic substances in the cavity,
It is well known that it can change the properties of a substance. The present invention relates to a composition containing a heme iron-containing material and cyclodextrins, which is obtained by adding cyclodextrins to a heme iron-containing material and stirring and kneading the mixture in the presence of water.
本発明においては、ヘム鉄含有物とは動物（牛、馬、豚
、羊等）の層殺体の血液由来のものを指す。具体的には
血液そのもの（乾燥したもの〉、或いはさらに精製した
ものが使用可能である。これを例示すれば、通常は血液
を採取し、凝固防止剤としてクエン酸すＩ・リウム、ヘ
パリン、ＥＤＴＡ２ナトリウム等の内の１つを適量添加
後、遠心分離等により赤血球を得、これに水を添加する
等して低張液に晒すと血球が破け、ヘモグロビンが溶液
中に得られるので、残渣を遠心分離等にて除き、上澄液
を乾燥するとヘム鉄含有量の比較的高いヘモグロビン粉
末が得られるので、このもの成るいはこれを増量剤とし
て通常用いられる基材を配合したもの等も使用できる。In the present invention, heme iron-containing substances refer to substances derived from the blood of slaughtered animals (cows, horses, pigs, sheep, etc.). Specifically, blood itself (dried) or further purified blood can be used. For example, blood is usually collected and treated with I-lium citrate, heparin, and EDTA2 as anticoagulants. After adding an appropriate amount of one of sodium, etc., red blood cells are obtained by centrifugation, etc., and when water is added to the red blood cells and exposed to a hypotonic solution, the blood cells are ruptured and hemoglobin is obtained in the solution. If the supernatant is removed by centrifugation and dried, a hemoglobin powder with a relatively high heme iron content can be obtained, so use this powder or a blend of it with a base material that is commonly used as an extender. can.
ヘモグロビン粉末は、このままでもヘム鉄含有物として
利用できるが、さらに精製することにより、ヘム鉄の含
有量を上げることも可能である。ヘム鉄を高純度で得る
には、牛や豚の血球を溶血したものを、食塩を少量添加
した熱水酢酸中に注ぎ込み、ｌ＼モグロビンを分解し、
適量の水を加えて放冷すると、色素部分が結晶として得
られ、本結晶はプロトポルフィリンの３価鉄銘塩でヘミ
ンともいわれるもので、これを還元する方法が有効であ
る。本方法によれば、ヘム鉄をかなりの純度で得ること
が可能となる。本発明においてはヘム鉄含有物とは上記
赤血球そのものや赤血球からのヘモグロビン或いはさら
に高純度のヘム鉄等をも包含する。当然のことながら、
純粋なヘム鉄をヘモグロビン粉末に混合したもの或いは
増量剤をこれらに添加したもの等、各純度のヘム鉄含有
品の混合物も含まれる。これらのうち、好適には検疫中
、豚の血液よりヘモグロビン画分を精製して得られる、
鉄を０．５〜１．５％程度含む粉末ヘム鉄含有物が用い
られる。Hemoglobin powder can be used as it is as a heme iron-containing material, but it is also possible to increase the heme iron content by further refining it. To obtain high-purity heme iron, hemolyzed cow or pig blood cells are poured into hot acetic acid with a small amount of salt added to decompose l\moglobin.
When an appropriate amount of water is added and allowed to cool, the pigment part is obtained as a crystal. This crystal is a trivalent iron salt of protoporphyrin, also called hemin, and an effective method is to reduce it. According to this method, it is possible to obtain heme iron with considerable purity. In the present invention, heme iron-containing substances include the above-mentioned red blood cells themselves, hemoglobin from red blood cells, and even highly purified heme iron. As a matter of course,
Mixtures of products containing heme iron of various purity levels are also included, such as pure heme iron mixed with hemoglobin powder or products with bulking agents added thereto. Among these, preferably obtained by purifying the hemoglobin fraction from pig blood during quarantine,
Powdered heme iron-containing material containing approximately 0.5 to 1.5% iron is used.
本発明にて、シクロデキストリン類とは、澱粉および／
又は澱粉の加水分解物にシクロデキストリングルカノト
ランスフェラーゼ（ＣＧＴａｓｅ）を作用させて精製さ
れる環状デキストリンの総称であり、構成するグルコー
スの数によりα型、β型、γ型が主要なものとして知ら
れており、さらに環状デキストリンの構成グルコースの
６位にグルコース又はマルトース、マルトトリオース等
が付加した分岐シクロデキストリン類が知られている。In the present invention, cyclodextrins refer to starch and/or
It is a general term for cyclic dextrins that are purified by the action of cyclodextrin glucanotransferase (CGTase) on starch hydrolyzate, and the main types are α-type, β-type, and γ-type depending on the number of glucose constituents. Furthermore, branched cyclodextrins are known in which glucose, maltose, maltotriose, etc. are added to the 6-position of the constituent glucose of the cyclic dextrin.
また、部分的に置換基（例えばメチル基）を導入したシ
クロデキストリン誘導体も使用可能である。本発明では
α−１β−１γ−シクロデキストリン、分岐シクロデキ
ストリン、上記シクロデキストリン誘導体或いはこれら
の混合物、さらにはこれらとデキストリンの混合物のい
ずれを使用しても良いが、通常はグルコース７個よりな
るβ−シクロデキストリンを主成分として用いるのがよ
い。Furthermore, cyclodextrin derivatives partially introduced with substituents (for example, methyl groups) can also be used. In the present invention, any of α-1β-1γ-cyclodextrin, branched cyclodextrin, the above-mentioned cyclodextrin derivatives or mixtures thereof, and mixtures of these and dextrins may be used, but usually β consisting of 7 glucose units is used. - It is preferable to use cyclodextrin as the main component.
本発明はヘム鉄含有物にシクロデキストリンを水の存在
下、混合、混練する方法にて行うものである。ヘム鉄含
有物に対するシクロデキストリン類の添加量は、ヘム鉄
含有物の精製度、血液由来の異味、異臭の程度により限
定的ではないが、ヘム鉄含有物固形分に対して、シクロ
デキストリンを固形分として５％以上の添加量にて、ヘ
ム鉄含有物の異味、異臭成分をマスキング可能である。The present invention is carried out by a method of mixing and kneading cyclodextrin with a heme iron-containing material in the presence of water. The amount of cyclodextrins added to the heme iron-containing material is not limited, depending on the degree of purification of the heme iron-containing material and the degree of blood-derived off-taste and odor. When added in an amount of 5% or more, it is possible to mask the off-taste and off-odor components of heme iron-containing substances.
ヘム鉄含有物に血液由来の異味、異臭成分が強く残存す
る場合は、比較的多量のシクロデキストリンを必要とす
るが、通常市販されている鉄として１％程度を含有する
ヘム鉄含有物の場合、ヘム鉄含有物固形分に対し、β−
シクロデキストリン１０％以上を添加し、水の存在下、
攪拌、混練後、乾燥すると異味、異臭がマスキングされ
なヘム鉄含有粉末が得られる。If blood-derived off-taste and odor components remain strongly in the heme iron-containing product, a relatively large amount of cyclodextrin is required, but in the case of heme iron-containing products that normally contain about 1% of iron on the market. , relative to the heme iron-containing solid content, β-
Adding 10% or more of cyclodextrin and in the presence of water,
After stirring and kneading, drying yields a heme iron-containing powder with no masking of off-taste and odor.
このとき添加する水の量は、混合攪拌が充分できればよ
く特に限定されないが、通常はヘム鉄含有物とシクロデ
キストリン類の合計固形分重量に対し、５０〜２５０％
が好適である。攪拌混合時間は、ヘム鉄含有物に存在す
る異味、異臭がシクロデキストリン類に包接されるのに
充分であればよく、攪拌強度が強ければ短時間で済むし
、弱ければ長時間を要する。通常ニーダ−等の比較的攪
拌が弱い攪拌機の場合、異味、異臭の程度によって変動
するが、３０分から２時間混合する。攪拌時の温度はヘ
ム鉄が温度に対して安定であるのでとくに限定されない
が、シクロデキストリン類による包接は５０℃以上では
効率が下がるので５０℃以下にて行うことが望ましい。The amount of water added at this time is not particularly limited as long as sufficient mixing and stirring can be achieved, but it is usually 50 to 250% of the total solid weight of the heme iron-containing material and cyclodextrins.
is suitable. The stirring and mixing time may be sufficient as long as it is sufficient for the foreign taste and odor present in the heme iron-containing material to be included in the cyclodextrins, and if the stirring intensity is strong, a short time is required, and if the stirring intensity is weak, a long time is required. In the case of a stirrer with relatively weak agitation such as a kneader, the mixture is mixed for 30 minutes to 2 hours, although this varies depending on the degree of off-taste and odor. The temperature during stirring is not particularly limited as heme iron is stable with respect to temperature, but since the efficiency of inclusion with cyclodextrins decreases above 50°C, it is desirable to carry out the stirring at a temperature below 50°C.
通常は常温にて攪拌、混練を行う。かくして得られなヘ
ム鉄含有物とシクロデキストリン類の混合物を適当な乾
燥器にて乾燥することにより、異味、異臭のマスキング
されたヘム鉄含有組成物の粉末が得られる。乾燥方法は
通常用いられる乾燥器であればよく、特に限定されない
が、経済的見地から棚弐通風乾燥器或い噴霧乾燥器が好
適に用いられる。棚式乾燥器の場合は、得られた乾物を
粉砕することが必要となる。得られた粉末に適宜酸味料
、甘味料、増量剤等を配合、製剤化してもよい。Stirring and kneading are usually performed at room temperature. By drying the thus obtained mixture of the heme iron-containing material and cyclodextrins in a suitable dryer, a powder of the heme iron-containing composition with masked off-taste and odor can be obtained. The drying method may be any commonly used dryer, and is not particularly limited, but from an economical point of view, a shelf dryer or a spray dryer is preferably used. In the case of a shelf dryer, it is necessary to crush the dried material obtained. The obtained powder may be mixed with an acidulant, a sweetener, a filler, etc. as appropriate to form a formulation.
［発明の効果］ 本発明の効果について実験例を示して説明する。[Effect of the invention] The effects of the present invention will be explained by showing experimental examples.
実験例
５００ｎＪ容ビーカーに表１に示す容量のβ−シクロデ
キストリンく商標名： ＲＩＮＧＤＥＸ−Ｂ、三楽（Ｉ
ル製造）を入れ、水２００ｍｇを加え、軽く混合しスラ
リー状にした。これに表１に示す容量のヘム鉄含有物（
商標名：Ｈｅｍ Ｆｅ、三菱化成食品１１販売〉を添加
し、常温下スターラーにて激しく６０分間混合後、凍結
乾燥器にて乾燥し、乳鉢にて破砕、粉末化した。対照と
して、シクロデキストリンの代わりにデキストリン（商
標名：パインデックス＃１００、松谷化学工業ｉｌｌ製
造）を表１に示す割合にて用い。Experimental Example: Add β-cyclodextrin with the capacity shown in Table 1 to a 500 nJ beaker. Trade name: RINGDEX-B, Sanraku (I).
200 mg of water was added and mixed lightly to form a slurry. Add to this a heme iron-containing substance (with a capacity shown in Table 1)
Trade name: Hem Fe, sold by Mitsubishi Kasei Foods 11> was added thereto, and the mixture was vigorously mixed in a stirrer at room temperature for 60 minutes, dried in a freeze dryer, and crushed and powdered in a mortar. As a control, dextrin (trade name: Pinedex #100, manufactured by Matsutani Chemical Industry Co., Ltd.) was used in the ratio shown in Table 1 instead of cyclodextrin.
β−シクロデキストリンの場合と同様に処理し、粉末を
得た。得られた粉末の評価を２０名のパネラ−にておこ
ない、異味、異臭の程度を評価した。結果を表１に示す
。A powder was obtained by processing in the same manner as in the case of β-cyclodextrin. The obtained powder was evaluated by 20 panelists to evaluate the degree of off-taste and off-odor. The results are shown in Table 1.
（以下、余白）
表１より、β−シクロデキストリンによる、ヘム鉄含有
物の異味、異臭抑制効果は明らかであり、デキストリン
を用いた場合、ヘム鉄含有物の９倍量の添加でも若干、
異味、異臭が弱くなる程度であった。β−シクロデキス
トリンの場合は、粉末乾燥物中の添加量が１０％よりほ
とんど異味、異臭が感じられなくなり、それ以上の添加
では全く異味、異臭は感じられなかった。(The following is a blank space) From Table 1, it is clear that β-cyclodextrin has an effect of suppressing the off-taste and off-odor of heme iron-containing products.
The off-taste and odor were only weakened. In the case of β-cyclodextrin, when the amount added to the dry powder was 10%, almost no off-taste or off-odor was felt, and no off-taste or off-odor was felt when it was added beyond that amount.
［実施例］
以下に実施例を示し、本発明を更に具体的に説明するが
、本発明はこの実施例によって何ら制限されるものでは
ない。[Example] The present invention will be explained in more detail with reference to Examples below, but the present invention is not limited to these Examples in any way.
実施型上
β−シクロデキストリン（商標名： ＲＩＮＧＤＥＸ−
８、三楽■製造＞２００ｇを５１容ビーカーにとり、こ
れに水を２．０１添加、スラリーにしておき、ヘム鉄含
有物（商標名：Ｈｅｍ Ｆｅ、三菱化成食品（珠販売
）１．０ｋｇを添加後、攪拌機にて常温下、激しく（約
７５０ｒｐｍ＞１時間撹拌した。得られた混合物を凍結
乾燥し、ＶＬ鉢にて粉砕後、１．１５ｋｇの粉末を得な
。得られた粉末は、ヘム鉄含有物特有の異味、異臭がな
くなっており、β−シクロデキストリンの異味、異臭の
マスキング効果が顕著であった。Practical β-cyclodextrin (trade name: RINGDEX-
8. Sanraku ■Production> Take 200g in a 51 volume beaker, add 2.0ml of water to it, make a slurry, and add 1.0kg of heme iron-containing material (trade name: Hem Fe, Mitsubishi Kasei Foods (Tama Sales)). After that, the mixture was stirred vigorously (approximately 750 rpm>1 hour) at room temperature using a stirrer. The resulting mixture was freeze-dried and ground in a VL bowl to obtain 1.15 kg of powder. The off-taste and off-odor characteristic of iron-containing substances were gone, and the masking effect of β-cyclodextrin on off-taste and off-odor was remarkable.
実施例２
α−シクロデキストリン（商標名： ＲＩＮＧＤＥＸ−
Ａ、三楽■製造）３０ｇを５００ｍＮ容ビーカーにとり
、これに水を２００ｍＩＪ添加し軽く混合後、ヘム鉄含
有物（商標名：Ｈｅｍ Ｆｅ、三菱化成食品■販売）
７０ｇを添加後、攪拌機にて常温下、激しく（約７５０
ｒｐｍ）１時間攪拌した。得られた混合物を凍結乾燥し
、乳鉢にて粉砕後、９９ｇの粉末を得た。得られた粉末
は、ヘム鉄含有物特有の異味、異臭がなくなっており、
α−シクロデキストリンの異味、異臭のマスキング効果
が顕著であった。Example 2 α-cyclodextrin (trade name: RINGDEX-
Place 30g of A, produced by Sanraku in a 500mN beaker, add 200mIJ of water to it, mix gently, and add heme iron-containing material (trade name: Hem Fe, sold by Mitsubishi Kasei Foods).
After adding 70g, stir vigorously (approximately 750g) at room temperature with a stirrer.
rpm) and stirred for 1 hour. The resulting mixture was freeze-dried and ground in a mortar to obtain 99 g of powder. The obtained powder is free of the unusual taste and odor characteristic of heme iron-containing substances.
The masking effect of α-cyclodextrin on off-taste and off-odor was remarkable.
実旌庭旦
γ−シクロデキストリン（商標名： ＲＩＮＧＤＥＸ−
Ｃ１三楽１１製造）３０ｇを５００ｎＪ容ビーカーニド
’）、コレに水を２００ｍＮ添加し軽く混合後、ヘム鉄
含有物（商標名：Ｈｅｍ Ｆｅ、三菱化成食品（ＩＩ
販売）７０ｇを添加後、攪拌機にて常温下、激しく（約
７５Ｏｒｐｍ）１時間攪拌した。得られた混合物を凍結
乾燥し、乳鉢にて粉砕後、９９ｇの粉末を得た。得られ
た粉末は、ヘム鉄含有物特有の異味、異臭がなくなって
おり、γ−シクロデキストリンの異味、異臭のマスキン
グ効果が顕著であった。Jitsengeidan γ-cyclodextrin (trade name: RINGDEX-
Add 30 g of C1 Sanraku 11 (manufactured by Sanraku 11) to a 500 nJ beaker nide'), add 200 mN of water to this, mix gently, and add heme iron-containing material (trade name: Hem Fe, Mitsubishi Kasei Foods (II)).
After adding 70 g of the product (commercially available), the mixture was vigorously stirred (approximately 75 Orpm) for 1 hour at room temperature using a stirrer. The resulting mixture was freeze-dried and ground in a mortar to obtain 99 g of powder. The obtained powder was free of the off-taste and odor characteristic of heme iron-containing substances, and had a remarkable masking effect on the off-taste and odor of γ-cyclodextrin.
実旌健ユ
部分メチル化β−シクロデキストリン（商標名： ＰＭ
ＣＤ、三楽■製造）３０ｇを５００ｍｇ容ビーカーにと
り、これに水を２００ｍ、Ｉｌ添加し軽く混合後、ヘム
鉄含有物（商標名： Ｈｅ ｍ Ｆ ｅ、三菱化成食
品■販売）７０ｇを添加後、攪拌機にて常温下、激しく
（約７５０ｒｐｍ）Ｌ時間攪拌した。得られた混合物を
凍結乾燥し、乳鉢にて粉砕後、９８ｇの粉末を得た。得
られた粉末は、ヘム鉄含有物特有の異味、異臭がなくな
っており、部分メチル化βシクロデキストリンの異味、
異臭のマスキング効果が顕著であった。Partially methylated β-cyclodextrin (trade name: PM
CD, manufactured by Sanraku ■) 30g was placed in a 500mg beaker, 200ml of water was added to it, and after mixing gently, 70g of heme iron-containing material (trade name: Hem Fe, sold by Mitsubishi Kasei Foods ■) was added. The mixture was stirred vigorously (about 750 rpm) for L hours at room temperature using a stirrer. The resulting mixture was freeze-dried and ground in a mortar to obtain 98 g of powder. The obtained powder is free of the off-taste and odor characteristic of heme iron-containing substances, and is free of the off-taste and odor of partially methylated β-cyclodextrin.
The effect of masking off-odors was remarkable.
火旌医旦
シクロデキストリン混合物（商標名：ＲＩＮＧＤＥＸＰ
、α−１β−１γ−シクロデキストリンおよび澱粉加水
分解物の混合品、シクロデキストリン類含有量５０％、
三楽ａ１製造）５０ｇを５００ｍＪ２容ビーカーにとり
、これに水を２００ｍ、ｆ）添加し軽く混合後、ヘム鉄
含有物（商標名：Ｈｅｍ Ｆｅ、三菱化成食品■販売
）５０ｇを添加後、撹拌機にて常温下、激しく（約７５
０ｒｐｍ）１時間攪拌した。得られた混合物を凍結乾燥
し、乳鉢にて粉砕後、９７ｇの粉末を得た。得られた粉
末は、ヘム鉄含有物特有の異味、異臭がなくなっており
、シクロデキストリン混合物の異味、異臭のマスキング
効果が顕著であった。Cyclodextrin mixture (trade name: RINGDEXP)
, a mixture of α-1β-1γ-cyclodextrin and starch hydrolyzate, cyclodextrin content 50%,
Take 50g of Sanraku a1 (produced by Mitsubishi Kasei Foods) into a 500mJ2 beaker, add 200m of water (f), mix gently, add 50g of heme iron-containing material (trade name: Hem Fe, sold by Mitsubishi Kasei Foods), and add to a stirrer. at room temperature, vigorously (approximately 75
0 rpm) for 1 hour. The resulting mixture was freeze-dried and ground in a mortar to obtain 97 g of powder. The obtained powder was free from the off-taste and odor characteristic of heme iron-containing substances, and had a remarkable masking effect on the off-taste and odor of the cyclodextrin mixture.
Claims (2)
なる組成物(1) Composition containing heme iron-containing material and cyclodextrins
下に混合し、ヘム鉄含有物の異味、異臭成分をシクロデ
キストリン類で包接せしめた特許請求の範囲第一項記載
のヘム鉄含有組成物(2) Heme iron-containing material according to claim 1, wherein the heme iron-containing material and cyclodextrins are mixed in the presence of water, and the off-taste and odor components of the heme iron-containing material are included in the cyclodextrins. Composition
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1032635A JP2602712B2 (en) | 1989-02-14 | 1989-02-14 | Heme iron-containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1032635A JP2602712B2 (en) | 1989-02-14 | 1989-02-14 | Heme iron-containing composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02212429A true JPH02212429A (en) | 1990-08-23 |
| JP2602712B2 JP2602712B2 (en) | 1997-04-23 |
Family
ID=12364317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1032635A Expired - Lifetime JP2602712B2 (en) | 1989-02-14 | 1989-02-14 | Heme iron-containing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2602712B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004250390A (en) * | 2003-02-21 | 2004-09-09 | Taisho Pharmaceut Co Ltd | Iron compound-mixed oral liquid |
| JP2006101806A (en) * | 2004-10-07 | 2006-04-20 | Matsutani Chem Ind Ltd | Food masking agent for iron, magnesium or zinc component |
| JP2015017136A (en) * | 2008-08-11 | 2015-01-29 | 第一三共株式会社 | Method for decreasing odor |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57156412A (en) * | 1981-03-24 | 1982-09-27 | Kyoritsu Yakuhin Kogyo Kk | Preparation containing dextromethorphan hydrobromide |
| JPS57175126A (en) * | 1979-11-16 | 1982-10-28 | Puritsupusu Purigerieeru Ab | Hem iron-enhanced amino acid medicine and manufacture of same from hem protein |
| JPS61130219A (en) * | 1984-11-30 | 1986-06-18 | Dainippon Pharmaceut Co Ltd | Meclofenoxate hydrochloride composition |
| JPS6236320A (en) * | 1985-08-09 | 1987-02-17 | Mitsubishi Chem Ind Ltd | Pilular composition composed mainly of hem or hemoglobin and production thereof |
| JPS62185011A (en) * | 1986-02-10 | 1987-08-13 | Tanpei Seiyaku Kk | Intestinal bactericidal agent preparation |
-
1989
- 1989-02-14 JP JP1032635A patent/JP2602712B2/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57175126A (en) * | 1979-11-16 | 1982-10-28 | Puritsupusu Purigerieeru Ab | Hem iron-enhanced amino acid medicine and manufacture of same from hem protein |
| JPS57156412A (en) * | 1981-03-24 | 1982-09-27 | Kyoritsu Yakuhin Kogyo Kk | Preparation containing dextromethorphan hydrobromide |
| JPS61130219A (en) * | 1984-11-30 | 1986-06-18 | Dainippon Pharmaceut Co Ltd | Meclofenoxate hydrochloride composition |
| JPS6236320A (en) * | 1985-08-09 | 1987-02-17 | Mitsubishi Chem Ind Ltd | Pilular composition composed mainly of hem or hemoglobin and production thereof |
| JPS62185011A (en) * | 1986-02-10 | 1987-08-13 | Tanpei Seiyaku Kk | Intestinal bactericidal agent preparation |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004250390A (en) * | 2003-02-21 | 2004-09-09 | Taisho Pharmaceut Co Ltd | Iron compound-mixed oral liquid |
| JP2006101806A (en) * | 2004-10-07 | 2006-04-20 | Matsutani Chem Ind Ltd | Food masking agent for iron, magnesium or zinc component |
| JP4550543B2 (en) * | 2004-10-07 | 2010-09-22 | 松谷化学工業株式会社 | Food masking agent for iron, magnesium or zinc components |
| JP2015017136A (en) * | 2008-08-11 | 2015-01-29 | 第一三共株式会社 | Method for decreasing odor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2602712B2 (en) | 1997-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000018257A1 (en) | Process for producing powdery acid-treated egg | |
| JP4215377B2 (en) | Chitosan-containing composition | |
| JP2002034592A (en) | Method for producing protein-zinc readily absorbable in body | |
| JP2003189820A (en) | Encapsulated carob fiber having improved product characteristics, method for producing the same and use of the same | |
| JPH02212429A (en) | Hemoferrum-containing composition | |
| JP2002187842A (en) | Processed product of kale and method for processing the same | |
| JP3253813B2 (en) | Nutritional composition containing metal-bound casein | |
| JPH09191855A (en) | Calcium potentiating agent | |
| JP2002065205A (en) | Beauty health food containing material derived from young leaf of wheat | |
| JP3769267B2 (en) | Zinc-enhanced food and method for producing the same | |
| JP3647945B2 (en) | Health food using odorless garlic | |
| JP4852681B2 (en) | Intestinal cytolytic activity inhibitor | |
| JP3231118B2 (en) | Ferrous iron stabilizer | |
| JPH03119964A (en) | Dark meat-derived peptide composition | |
| JP2889921B2 (en) | Manufacturing method of granular foods from umeboshi, soy sauce and dandelion dried roots | |
| JPH09132531A (en) | Composition for additive to liquid food and liquid food | |
| JP2001226401A (en) | Calcium-phosphorylated starch complex and method of preparing the same | |
| JPH04158761A (en) | Peptide-containing and iron component enriched food | |
| JP2962890B2 (en) | Mineral-bound dietary fiber and method for producing the same | |
| JP3807660B2 (en) | Powdered soy protein food | |
| JPH03160951A (en) | Hemoferrum-containing biscuit | |
| JP2896473B2 (en) | Iron-reinforced bean jam | |
| JPH0356707B2 (en) | ||
| JP2896472B2 (en) | Heme iron fortified food with miso | |
| JPH0472827B2 (en) |